Mytesi is well tolerated, with a low incidence of adverse events

The ADVENT clinical trial reported a low rate of adverse events, compared to placebo.

There were no clinically relevant drug-drug interactions, or effects on CD4+ T cell counts or viral load1,2
There were no clinically relevant drug-drug interactions, or effects on CD4+ T cell counts or viral load1,2

The most common adverse reactions occurring at a rate greater than placebo were2:

Mytesi may provide
symptomatic relief of noninfectious
HIV-related diarrhea in PLWH on ART.

LEARN ABOUT MYTESI EFFICACY

Mytesi offers convenient,
twice-daily dosing.

SEE MYTESI DOSING INFORMATION

References:
1. Mytesi [package insert]. San Francisco, CA: Napo Pharmaceuticals. 2018. 2. MacArthur R, Harkins TN, Brown SJ, et al. Efficacy and safety of Crofelemer for non-infectious diarrhea in HIV-seropositive individuals (ADVENT Trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials. 2013;14(6):261-273.